Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Nozaki, Yuichi ^a,b   Fujita, Koji ^a   Wada, Koichiro ^c   Yoneda, Masato ^a   Kessoku, Takaomi ^a   Shinohara, Yoshiyasu ^a   Imajo, Kento ^a   Ogawa, Yuji ^a   Nakamuta, Makoto ^d   Saito, Satoru ^a   Masaki, Naohiko ^e   Nagashima, Yoji ^a   Terauchi, Yasuo ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e National Center for Global Health and Medicine   (Japan)

Author keywords

Fibrosis; Inflammation; NASH; NF kB; NOS

Indexed keywords

ALANINE AMINOTRANSFERASE; COLLAGEN TYPE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA 1; PLATELET DERIVED GROWTH FACTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARRIER PROTEIN; CYTOKINE; DGAT2 PROTEIN, MOUSE; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; MLXIPL PROTEIN, MOUSE; NUCLEAR PROTEIN; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIMP1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINEAGE; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FOLLOW UP; GENE EXPRESSION REGULATION; HEPATITIS; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIPID DIET; LIPID STORAGE; LIVER FIBROSIS; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; STELLATE CELL; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPLICATION; DEFICIENCY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETICS; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; TIME FACTOR;

ANIMALS; CARRIER PROTEINS; COLLAGEN TYPE I; CYTOKINES; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIET, HIGH-FAT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FATTY ACIDS, NONESTERIFIED; FOLLOW-UP STUDIES; GENE EXPRESSION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR PROTEINS; PLATELET-DERIVED GROWTH FACTOR; PPAR ALPHA; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84926318551     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0269-3     Document Type: Article

References (36)

1. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842-5.
2. Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol. 2009;51:548-56.
3. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50(3):772-80.
4. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012;3;16(1):44-54.
5. Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, Kaneki M. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes. 2005;54(5):1340-8.
6. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001;7(10):1138-43.
7. Tsuchiya K, Sakai H, Suzuki N, Iwashima F, Yoshimoto T, Shichiri M, et al. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. Endocrinology. 2007;148(10):4548-56.
8. Chen T, Zamora R, Zuckerbraun B, Billiar TR. Role of nitric oxide in liver injury. Curr Mol Med. 2003;3(6):519-26.
9. Rockey DC, Chung JJ. Regulation of inducible nitric oxide synthase and nitric oxide during hepatic injury and fibrogenesis. Am J Physiol. 1997;273(1 Pt 1):G124-30.
10. Cornejo P, Fernández V, Vial MT, Videla LA. Hepatoprotective role of nitric oxide in an experimental model of chronic iron overload. Nitric Oxide. 2007;16(1):143-9.
11. Wang GS, Liu GT. Role of nitric oxide in immunological liver damage in mice. Biochem Pharmacol. 1995;49(9):1277-81.
12. Gu Q, Yang X, Lin L, Li S, Li Q, Zhong S, Et al. Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. Hepatology. 2014; [Epub ahead of print].
13. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 2012;159(6):477-86.
14. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002;43(5):805-14.
15. Toshima G, Iwama Y, Kimura F, Matsumoto Y, Miura M, Takahashi J, et al. LipoSERCH® Analytical GP-HPLC method for lipoprotein profiling and its applications. J Biol Macromol. 2013;13(2):21-32.
16. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117(1):246-57.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
18. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583-91.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509.
20. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6(12):3051-64.
21. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16(2):185-94.
22. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003;38(1):133-40.
23. Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary condition. Gut. 2009;58(12):1637-43.
24. Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, Watanabe S, et al. Influence of inducible nitric oxide syntahse polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res. 2009;39(10):963-71.
25. Vos TA, Gouw AS, Klok PA, Havinga R, Van Goor H, Huitema S, et al. Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology. 1997;113(4):1323-33.
26. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster Jr JR. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;24;273(30):18709-13.
27. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 2001;166(6):3873-81.
28. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366-74.
29. Soufi N, Hall AM, Chen Z, Yoshino J, Collier SL, Mathews JC, et al. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities, but not inflammation and injury in mice. J Biol Chem. 2014; [Epub ahead of print].
30. Shindo N, Fujisawa T, Sugimoto K, Nojima K, Oze-Fukai A, Yoshikawa Y, et al. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol. 2010;52(6):903-12.
31. Becerril S, Rodríguez A, Catalán V, Sáinz N, Ramírez B, Collantes M, et al. Deletion of inducible nitric-oxide synthase in leptin-deficient mice improves brown adipose tissue function. PLoS One. 2010;5(6):e10962.
32. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48(2):670-8. Review.
33. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem. 1995;270(23):14214-9.
34. Cha HN, Kim YW, Kim JY, Kim YD, Song IH, Min KN, et al. Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Gerontol. 2010;45(9):711-8.
35. Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? Aging Cell. 2013;12(6):950-4.
36. Fontana L, Zhao E, Amir M, Dong H, Tanaka K, Czaja MJ. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis. Hepatology. 2013;57(3):995-1004.